全文获取类型
收费全文 | 575篇 |
免费 | 49篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 74篇 |
妇产科学 | 11篇 |
基础医学 | 52篇 |
口腔科学 | 38篇 |
临床医学 | 66篇 |
内科学 | 147篇 |
皮肤病学 | 10篇 |
神经病学 | 32篇 |
特种医学 | 73篇 |
外科学 | 42篇 |
综合类 | 9篇 |
一般理论 | 1篇 |
预防医学 | 28篇 |
眼科学 | 4篇 |
药学 | 30篇 |
肿瘤学 | 14篇 |
出版年
2021年 | 5篇 |
2020年 | 2篇 |
2019年 | 7篇 |
2018年 | 5篇 |
2017年 | 5篇 |
2016年 | 4篇 |
2015年 | 12篇 |
2014年 | 10篇 |
2013年 | 21篇 |
2012年 | 11篇 |
2011年 | 17篇 |
2010年 | 21篇 |
2009年 | 18篇 |
2008年 | 15篇 |
2007年 | 21篇 |
2006年 | 9篇 |
2005年 | 11篇 |
2004年 | 11篇 |
2003年 | 16篇 |
2002年 | 13篇 |
2001年 | 12篇 |
2000年 | 8篇 |
1999年 | 10篇 |
1998年 | 22篇 |
1997年 | 38篇 |
1996年 | 34篇 |
1995年 | 21篇 |
1994年 | 24篇 |
1993年 | 22篇 |
1992年 | 7篇 |
1991年 | 18篇 |
1990年 | 16篇 |
1989年 | 17篇 |
1988年 | 19篇 |
1987年 | 14篇 |
1986年 | 17篇 |
1985年 | 12篇 |
1984年 | 7篇 |
1983年 | 16篇 |
1982年 | 18篇 |
1981年 | 15篇 |
1980年 | 6篇 |
1979年 | 3篇 |
1978年 | 2篇 |
1977年 | 2篇 |
1976年 | 3篇 |
1975年 | 2篇 |
1972年 | 2篇 |
1970年 | 2篇 |
1968年 | 4篇 |
排序方式: 共有632条查询结果,搜索用时 546 毫秒
81.
Fifty-seven children between the ages of 3 and 17 years with acute lymphoblastic leukemia (ALL) in chemotherapy-induced second bone marrow remission were given cyclophosphamide, total body irradiation, and bone marrow transplants from HLA-matched donors. Sixteen died of transplant- related complications. Eighteen relapsed between 56 and 833 days after transplantation, and 16 died of leukemia. Two survive in remission off treatment following chemotherapy. Twenty-three survive in continuous remission from 1.4 to 10.4 years after transplantation and the actuarial analysis shows disease-free survival of 40% with a plateau extending from 2.5 to 10.4 years. 相似文献
82.
83.
Winton EF; Srinivasiah J; Kim BK; Hillyer CD; Strobert EA; Orkin JL; Swenson RB; McClure HM; Myers LA; Saral R 《Blood》1994,84(1):65-73
Using a recently developed hepsulfam-induced pancytopenia model in rhesus macaques, we have studied the effects of recombinant human interleukin-6 (rhIL-6) and rhIL-3 on marrow regeneration. Control animals were given hepsulfam (1.5 g/m2 by a single 30-minute intravenous [i.v.] injection, n = 4), while study animals received hepsulfam followed by rhIL-6, rhIL-3, or a combination of rhIL-6 and rhIL-3 (n = 3 per study group). Each cytokine was administered by once- daily subcutaneous (SC) injection (15 micrograms/kg/d) for 3 weeks beginning the day after chemotherapy (days 2 through 22). Mean platelet counts in control animals were < 100,000/microL on days 15 through 24, with 50% of the counts < 50,000/microL and two of four animals requiring platelet transfusion. In the rhIL-6- and rhIL-6/rhIL-3- treated groups, the nadir mean platelet counts were 164,000 +/- 58,700/microL and 162,300 +/- 23,800/microL, respectively, and occurred on day 15. Platelet counts in the rhIL-3-treated group were similar to those in controls. Mean absolute neutrophil counts (ANCs) < 1,000/microL occurred on days 10 through 29 in control animals, days 8 through 15 in rhIL-6-treated animals, and days 6 through 8 and 13 in rhIL-6/rhIL-3-treated animals. The frequency of ANCs < 500/microL was significantly less in the rhIL-6- and rhIL-6/rhIL-3-treated groups versus control groups (2.7 +/- 0.6 and 2.0 +/- 1.0 vs 7.0 +/- 1.4 occurrences, respectively; P < .05). rhIL-3-treated animals had ANCs similar to those in controls; one animal died with septicemia on day 21. Monkeys receiving rhIL-6 were significantly more anemic during the cytokine administration period; however, the anemia resolved by day 24. Coadministration of rhIL-3 and rhIL-6 partially corrected the anemia. The data indicate that rhIL-6 prevents significant thrombocytopenia and shortens the neutropenic period in this chemotherapy model. 相似文献
84.
One hundred six patients underwent extracorporeal shock wave lithotripsy for cholelithiasis. Of these, 28 patients underwent cholangiographically guided lithotripsy for bile duct stones to assist nonoperative stone removal by endoscopic or radiologic intervention. Fragmentation occurred in 20 of 28 cases (71%) with an average of two lithotripsy sessions. Hemobilia was observed in four patients (14%) for a 24-hour period. Seventy-eight of the 106 were outpatients with symptomatic cholecystolithiasis with one to five calculi who underwent cholecystographic or ultrasound-(US) guided shock wave lithotripsy as definitive therapy. US examination showed stone fragmentation in 86% of cases. With an average of 1.6 treatment sessions and 4,750 shocks, fragments were 4 mm or smaller in 46% of patients. Nine percent of patients had no fragments after an average of 10 weeks, but long-term follow-up is not yet available. Two patients developed acute pancreatitis attributable to fragment passage and one patient acute cholecystitis, likely due to cystic duct obstruction by a fragment. 相似文献
85.
86.
87.
88.
89.
90.
Dr. Gary V Heller M.D. Ph.D. Dr. Marandapalli Sridharan M.D. Dr. John Morse M.D. Dr. Stephen Glasser M.D. Dr. C. L. Beach Pharm.D. Diltiazem CD Study Group 《Pharmacotherapy》1997,17(4):760-766
Study Objective . To determine the safety and efficacy of diltiazem CD 180 mg administered once/day in patients with chronic stable angina inadequately controlled with β-blockers, long-acting nitrates, or both. Design . Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Setting . Medical clinics in the private and academic sectors. Patients . Of 172 patients, 170 completed the 2-week double-blind treatment period. Interventions . Patients received either diltiazem CD 180 mg or placebo once/day in combination with existing antianginal therapy. Measurements and Main Results . The time to termination of exercise tolerance testing, 24 hours after the dose increased significantly in the diltiazem CD group (37.2 sec) compared with the placebo group (21.3 sec, p=0.0438). Time to onset of angina during exercise testing also increased (57.6 vs 35.0 sec, respectively, p=0.0324), as did time to moderate angina (37.5 vs 20.6 sec, respectively, p=0.0354). The rates of total angina attacks and of angina attacks on exertion were significantly reduced in the diltiazem CD group versus placebo (p<0.05). Significant reductions in systolic and diastolic blood pressures and heart rate-blood pressure product measured at rest, submaximum exercise, and exercise termination were observed in diltiazem CD-treated patients compared with placebo (p<0.05). The frequency of treatment-related adverse events was identical in the two groups, 15.1%. Conclusion . Diltiazem CD 180 mg once/day is an effective, safe, and beneficial initial dosage when added to existing antianginal therapy. 相似文献